Combat Medical's HIVEC HEAT Trial Highlights Potential for Bladder Cancer Treatment
Combat Medical has announced an update on its HIVEC HEAT trial at the American Urological Association Annual Meeting. The trial is a phase 3 study investigating the use of hyperthermic chemotherapy for bladder-sparing treatment in patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. The study, conducted across 25 sites in the UK, aims to support FDA registration. The trial uses Combat's bladder recirculation system to deliver chemotherapy at controlled temperatures, potentially increasing anti-tumor activity while preserving the bladder. The trial has shown promising results, with up to 83% disease-free survival after one year and a bladder preservation rate of nearly 80% after two years. 
